Among 26 analysts covering U.S. Silica (NYSE:SLCA), 23 have Buy rating, 1 Sell and 2 Hold. Therefore 88% are positive. U.S. Silica has $70 highest and $14 lowest target. $40.31’s average target is 11.20% above currents $36.25 stock price. U.S. Silica had 85 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of U.S. Silica Holdings, Inc. (NYSE:SLCA) earned “Neutral” rating by DA Davidson on Monday, June 13. The firm earned “Buy” rating on Thursday, July 20 by RBC Capital Markets. The firm earned “Buy” rating on Tuesday, May 30 by Jefferies. The rating was maintained by RBC Capital Markets on Thursday, October 29 with “Sector Perform”. The rating was maintained by Oppenheimer with “Perform” on Thursday, July 30. As per Wednesday, November 8, the company rating was maintained by Credit Suisse. The rating was upgraded by Johnson Rice on Monday, November 7 to “Buy”. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, November 8. DA Davidson initiated the shares of SLCA in report on Monday, December 7 with “Buy” rating. As per Monday, November 13, the company rating was maintained by Jefferies.
CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) had an increase of 75% in short interest. CTTC’s SI was 2,100 shares in January as released by FINRA. Its up 75% from 1,200 shares previously. The stock increased 8.91% or $0.01 during the last trading session, reaching $0.11. About shares traded. Calmare Therapeutics Incorporated (OTCMKTS:CTTC) has 0.00% since January 18, 2017 and is . It has underperformed by 16.70% the S&P500.
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. The company has market cap of $3.34 million. The Company’s flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. It currently has negative earnings. The firm was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014.
Analysts await U.S. Silica Holdings, Inc. (NYSE:SLCA) to report earnings on February, 28. They expect $0.56 earnings per share, up 722.22% or $0.65 from last year’s $-0.09 per share. SLCA’s profit will be $45.50 million for 16.18 P/E if the $0.56 EPS becomes a reality. After $0.53 actual earnings per share reported by U.S. Silica Holdings, Inc. for the previous quarter, Wall Street now forecasts 5.66% EPS growth.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.